<DOC>
	<DOCNO>NCT00122330</DOCNO>
	<brief_summary>The primary objective evaluate safety efficacy eculizumab transfusion dependent patient hemolytic PNH .</brief_summary>
	<brief_title>Study Using Eculizumab Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria ( PNH ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Must require least 4 transfusion past 12 month PNH type III red blood cell ( RBC ) clone flow cytometry &gt; 10 % Lactate dehydrogenase ( LDH ) level &gt; 1.5 x upper limit normal Platelet count &gt; 100,000/mm3 Patient take erythropoietin must stable dose least 26 week Patient take immunosuppressant must stable dose least 26 week Patient take corticosteroid must stable dose least 4 week Patient take coumadin must stable INR least 4 week Patient take iron supplement folic acid must stable dose 4 week Willing able give write informed consent Must avoid conception Mean hemoglobin level prior transfusion previous 12 month &gt; 10.5 gm/dl Absolute neutrophil count &lt; 500/ul Active bacterial infection Hereditary complement deficiency Participation investigational drug trial exposure investigational agent , device , procedure within 30 day Pregnant , breastfeeding , intend conceive History meningococcal disease History bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>